Sakar Healthcare Limited (SAKAR) fundamentals
Sakar Healthcare Limited is a listed company in Pharmaceuticals & Biotechnology, part of the Healthcare sector, listed on the NSE as SAKAR (ISIN INE732S01012). This page carries its reported financials, balance sheet, cash flow, shareholding pattern and valuation ratios.
What Sakar Healthcare Limited does
Sakar Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in manufacturing of pharmaceutical products providing liquid orals, cephalosporin tablets, capsules, dry powder syrup, dry powder injections, liquid injectables (SVP) in ampoules and vials & lyophilized injections. The Company's oncology products include oral solid dosage (tablet & capsule), liquid injection, lyophilized injection, active pharmaceutical ingredient (API), CDMO products and CRAMs. It has a presence across the regions of Africa (Anglo & Francophone), SEASIA, CIS, Latin & Central America and in Europe. It operates in over 50 countries globally and has approximately 292 registered products. It exports to Southeast Asia, Asia, Africa-Anglo & Francophone, MENA, America, covering around 38 countries with more than 250 brands registered.
Valuation and market data
| Last close | ₹1158.55 |
|---|---|
| Market capitalisation | ₹2,578 crore |
| Enterprise value | ₹2,624 crore |
| P/E (TTM) | 0.00 |
| Price to book | 7.94 |
| Price to sales (TTM) | 9.36 |
| Book value per share | ₹145.87 |
| Dividend yield | 0.00% |
| Sector | Healthcare |
| Industry | Pharmaceuticals & Biotechnology |
| Listed since | Thu Apr 11 |
Annual results
| Period | Revenue | Profit before tax | Net profit | EPS |
|---|---|---|---|---|
| Mar 2026 | ₹254 crore | ₹40 crore | ₹30 crore | 13.70 |
| Mar 2025 | ₹179 crore | ₹22 crore | ₹18 crore | 7.97 |
| Mar 2024 | ₹157 crore | ₹16 crore | ₹12 crore | 5.64 |
| Mar 2023 | ₹138 crore | ₹17 crore | ₹13 crore | 6.75 |
| Mar 2022 | ₹130 crore | ₹19 crore | ₹15 crore | 9.96 |
Figures are as reported (standalone), in ₹ crore.
Shareholding pattern
As of Jun 2026:
| Promoters | 52.5% |
|---|---|
| Foreign institutions (FII) | 12.1% |
| Mutual funds | 0.0% |
| Other domestic institutions | 11.4% |
| Retail and others | 24.0% |
More on BreakPoint
FundaX company research covers every listed company with reported financials. BreakPoint Pro adds the BreakPoint iQ score, the screener and the multibagger board.
Data is sourced from exchange filings and vendor feeds and is for research, not investment advice. Figures can be restated by the company after publication.